investorscraft@gmail.com

Stoke Therapeutics, Inc. (STOK)

Previous Close
$11.48
Sector Valuation Confidence Level
High
Valuation methodValue, $Upside, %
Artificial intelligence (AI)81.14607
Intrinsic value (DCF)0.00-100
Graham-Dodd Methodn/a
Graham Formulan/a

Company Information

45 Wiggins Avenue
Bedford, MA 01730
United States
Phone: 781 430 8200
Industry: Biotechnology
Sector: Healthcare
CEO: Mr. Ian F. Smith A.C.A., C.P.A.
Full Time Employees: 128

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

HomeMenuAccount